Toggle light / dark theme

“People on metformin have 30% lower rates of almost every kind of cancer. It delays cognitive decline. Even people with diabetes who are obese and have more disease to start with but are on metformin have lower mortality rates than people without diabetes who aren’t on the drug.”

What he says is born out in numerous studies. Overall, this safe, super-cheap, decades-old drug not only treats diabetes, but it also seems to delay and compress the years of chronic illness associated with the final stage of life and extend what geroscientists call the “healthspan.”

Metformin is just one of many medications, including other old ones and some brand new inventions, that academic researchers and biotech startups are exploring to slow, stop, or perhaps even reverse aging.

For the first time, a researcher at the University of Delaware College of Health Sciences in collaboration with a team at the National Institute on Aging, a division of the National Institutes of Health, has determined that the naturally occurring dietary supplement known as nicotinamide riboside (NR) can enter the brain.

The discovery was made by Christopher Martens, assistant professor of kinesiology and applied physiology and director of the Delaware Center for Cognitive Aging Research, and Dr. Dimitrios Kapogiannis, a senior investigator at the National Institute on Aging. The finding is significant because it supports the idea that NR, upon reaching the brain, can alter the metabolism of relevant biological pathways involved in like Alzheimer’s. Their work was recently published in the journal Aging Cell.

Upon consumption, NR is readily converted into nicotinamide adenine dinucleotide (NAD+), which is critical to cellular repair and the repair of damaged DNA.

In this video we run through a recent study which analyzed data in the UK Biobank to see if patients taking lithium as an anti-psychotic saw extended lifespan of those using a different type of medication and they found that they did.

📃Papers in this video.
Lithium treatment extends human lifespan: findings from the UK Biobank.
_https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925675/_
Low-dose lithium uptake promotes longevity in humans and metazoans.
_https://pubmed.ncbi.nlm.nih.gov/21301855/_

*Renue By Science* 10% : _https://tinyurl.com/4yrf4tv3_
Use SUBMHS when buying subscriptions for a continued discount of renewal orders.
*DoNotAge* 10% discount code MODERNHEALTHSPAN _https://donotage.org/products/_
*ProHealth* 10% discount Code MODERN : _https://prohealth.pxf.io/c/3176409/1541296/17976_
*NOVOS* Core & NOVOS Boost $5 off with code MODERN5 _https://novoslabs.com/?ref=3957_
*Bulletproof* 15% off with coupon code: HEALTHSPAN15: _https://tinyurl.com/4npjk5vp_

☕If you would like to support our channel, we’d love a coffee…thank you! _https://www.buymeacoffee.com/mhealthspan_

The above links are affiliate links so I will earn a commission when they or the accompanying discount codes are used to purchase products.

*******************************

19 minutes in, “At this point I think things are going pretty damned well,” when talking about if the middle-aged will benefit.


Life-Extension pioneer Dr. Aubrey De Grey discusses the LEV & SENS foundations, the latest trends in anti-aging research, new animal trials anticipated to double or triple life expectancy, and increased social acceptance for the disease model of aging.

Dr. Aubrey de Grey is President and CSO at the Longevity Escape Velocity (LEV) Foundation and Co-founder at the SENS Research Foundation. He’s also the author of The Mitochondrial Free Radical Theory of Aging and co-author of Ending Aging.

Dr. De Grey is generally recognized as one of world’s leading experts in longevity research, and is an international adjunct professor of the Moscow Institute of Physics and Technology, a fellow of the Gerontological Society of America, the American Aging Association, and also the Institute for Ethics and Emerging Technologies.

Dr. De Grey has a BA in Computer Science, studies in Bioinformatics, and a PhD in Biology from the University of Cambridge.

Glioblastomas are the most common malignant tumors of the adult brain. They resist conventional treatment, including surgery, followed by radiation therapy and chemotherapy. Despite this armamentarium, glioblastomas inexorably recur.

In a new study published in Nature Communications, Isabelle Le Roux (CNRS) and her colleagues from the “Genetics and development of brain tumors” team at Paris Brain Institute have shown that the elimination of senescent cells, i.e., cells that have stopped dividing, can modify the tumor ecosystem and slow its progression. These results open up new avenues for treatment.

Glioblastoma, the most common adult brain cancer, affects 2 to 5 in 100,000 individuals. While the incidence of the disease is highest in those between 55 and 85 years old, it is increasing in all age groups. This effect can’t be attributed to improved diagnostic techniques alone, suggesting the influence of environmental factors hitherto unidentified.

Can we objectively tell how fast we are aging? With a good measure, scientists might be able to change our rate of aging to live longer and healthier lives. Researchers know that some people age faster than others and have been trying to concisely measure the internal physiological changes that lead to deteriorating health with age.

For years, researchers have been using clinical factors normally collected at physicals, like hypertension, cholesterol and weight, as indicators to predict aging. The idea was that these measures could determine whether someone is a fast or slow ager at any point in their . But more recently, researchers have theorized that there are other biological markers that reflect aging at the molecular and cellular level. This includes modifications to a person’s genetic material itself, or epigenetics.

While each person has a that largely does not change over their lifetime, to their genetic material that occur throughout life can change which genes are turned on or off and lead to more rapid aging. These changes typically involve the addition of methyl groups to DNA and are influenced by social and environmental exposures, such as , smoking, pollution and depression.

Telomeres – the protective caps at the tips of chromosomes – can encode two proteins, something that was previously thought impossible, new research has suggested. The discovery of genetic information coding for these proteins, one of which is elevated in some human cancers, could have huge ramifications for the fields of health, medicine, and cell biology.

“Discovering that telomeres encode two novel signaling proteins will change our understanding of cancer, aging, and how cells communicate with other cells,” study author Jack Griffith, the Kenan Distinguished Professor of Microbiology and Immunology at the University of North Carolina at Chapel Hill, said in a statement.

“Based on our research, we think simple blood tests for these proteins could provide a valuable screen for certain cancers and other human diseases,” Griffith, who is also a member of the UNC Lineberger Comprehensive Cancer Center, added. “These tests also could provide a measure of ‘telomere health,’ because we know telomeres shorten with age.”